Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer

Danni Li, Hanching Chiu, Vinita Gupta, Daniel Wan-Yui Chan

Research output: Contribution to journalArticle

Abstract

Background: Assays used for discovery of biomarkers should be robust and high-throughput, capable of analyzing a sufficiently large number of samples over a sufficiently long period of time with good precision. Methods: We evaluated the analytical performance of the Bio-Plex Pro™ Human Cancer Biomarker Panel 1, a 16-plex multiplex immunoassay, in serum for composite profiling of angiogenic factors. Because prostate cancer progression and metastasis are pathological events closely linked to angiogenesis, serum angiogenic factors are ideal candidates as prognostic biomarkers. Results: Our 5-day evaluation indicated that all 16 assays in the panel had good reproducibility (total precisions over 5 independent plates in 5 days of

Original languageEnglish (US)
Pages (from-to)1506-1511
Number of pages6
JournalClinica Chimica Acta
Volume413
Issue number19-20
DOIs
StatePublished - Oct 9 2012

Fingerprint

Angiogenesis Inducing Agents
Biomarkers
Immunoassay
Assays
Prostatic Neoplasms
Tumor Biomarkers
Serum
Throughput
Neoplasm Metastasis
Composite materials

Keywords

  • Aggressive prostate cancer
  • Immunoassay
  • Multiplex
  • Serum angiogenic factors

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. / Li, Danni; Chiu, Hanching; Gupta, Vinita; Chan, Daniel Wan-Yui.

In: Clinica Chimica Acta, Vol. 413, No. 19-20, 09.10.2012, p. 1506-1511.

Research output: Contribution to journalArticle

@article{17d28905fba44e3a85b51935a3cb8f4d,
title = "Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer",
abstract = "Background: Assays used for discovery of biomarkers should be robust and high-throughput, capable of analyzing a sufficiently large number of samples over a sufficiently long period of time with good precision. Methods: We evaluated the analytical performance of the Bio-Plex Pro™ Human Cancer Biomarker Panel 1, a 16-plex multiplex immunoassay, in serum for composite profiling of angiogenic factors. Because prostate cancer progression and metastasis are pathological events closely linked to angiogenesis, serum angiogenic factors are ideal candidates as prognostic biomarkers. Results: Our 5-day evaluation indicated that all 16 assays in the panel had good reproducibility (total precisions over 5 independent plates in 5 days of",
keywords = "Aggressive prostate cancer, Immunoassay, Multiplex, Serum angiogenic factors",
author = "Danni Li and Hanching Chiu and Vinita Gupta and Chan, {Daniel Wan-Yui}",
year = "2012",
month = "10",
day = "9",
doi = "10.1016/j.cca.2012.06.017",
language = "English (US)",
volume = "413",
pages = "1506--1511",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "19-20",

}

TY - JOUR

T1 - Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer

AU - Li, Danni

AU - Chiu, Hanching

AU - Gupta, Vinita

AU - Chan, Daniel Wan-Yui

PY - 2012/10/9

Y1 - 2012/10/9

N2 - Background: Assays used for discovery of biomarkers should be robust and high-throughput, capable of analyzing a sufficiently large number of samples over a sufficiently long period of time with good precision. Methods: We evaluated the analytical performance of the Bio-Plex Pro™ Human Cancer Biomarker Panel 1, a 16-plex multiplex immunoassay, in serum for composite profiling of angiogenic factors. Because prostate cancer progression and metastasis are pathological events closely linked to angiogenesis, serum angiogenic factors are ideal candidates as prognostic biomarkers. Results: Our 5-day evaluation indicated that all 16 assays in the panel had good reproducibility (total precisions over 5 independent plates in 5 days of

AB - Background: Assays used for discovery of biomarkers should be robust and high-throughput, capable of analyzing a sufficiently large number of samples over a sufficiently long period of time with good precision. Methods: We evaluated the analytical performance of the Bio-Plex Pro™ Human Cancer Biomarker Panel 1, a 16-plex multiplex immunoassay, in serum for composite profiling of angiogenic factors. Because prostate cancer progression and metastasis are pathological events closely linked to angiogenesis, serum angiogenic factors are ideal candidates as prognostic biomarkers. Results: Our 5-day evaluation indicated that all 16 assays in the panel had good reproducibility (total precisions over 5 independent plates in 5 days of

KW - Aggressive prostate cancer

KW - Immunoassay

KW - Multiplex

KW - Serum angiogenic factors

UR - http://www.scopus.com/inward/record.url?scp=84863206381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863206381&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2012.06.017

DO - 10.1016/j.cca.2012.06.017

M3 - Article

C2 - 22722017

AN - SCOPUS:84863206381

VL - 413

SP - 1506

EP - 1511

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 19-20

ER -